

PHARMACEUTICAL 2021

CATALYST PHARMACEUTICALS INC. Rank 2 of 402



Selling, General and Administrative Cost of Goods Sold -10.0% Intangible Assets -0.164% Research and Development 25.6% Property and Equipment -0.0873% Assets, Current 0.389% Other Revenues 86.8% Other Expenses 43.6% Other Assets 0.260% -10.0% 0.260% -0.0873% 86.8% 25.6% -6.11% -0.164% 0.389% Liabilities Other Net Other Liabilities. Liabilities 48.1% Non-Current 44.3% 86.8% 53.1% 2.69% 48.1% 44.3% 53.1% 78.7% 143% -40.1% Comprehensive Net Income 143% Stockholders Equity 115% 115% 143% Capital Ratio





PHARMACEUTICAL 2021



CATALYST PHARMACEUTICALS INC.



Rank 2 of 402

The relative strengths and weaknesses of CATALYST PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CATALYST PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 143% points. The greatest weakness of CATALYST PHARMACEUTICALS INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 341%, being 294% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	159,244
Cost of Goods Sold	17,039
Intangible Assets	0
Liabilities, Current	22,756
Liabilities, Non-Current	0
Other Assets	32,980
Other Compr. Net Income	22
Other Expenses	-33,093
Other Liabilities	0
Other Net Income	587
Other Revenues	119,073
Property and Equipment	130
Research and Development	16,497
Selling, General and Administrative Expense	44,234

Output Variable	Value in 1000 USD
Assets	192,354
Liabilities	22,756
Expenses	44,677
Revenues	119,073
Stockholders Equity	169,598
Net Income	74,983
Comprehensive Net Income	74,994
Economic Capital Ratio	341%

